Medulloblastoma — Trials

Medulloblastoma — Trials · CancerIndex

Clinical trials

Registered studies

204 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 61
Recruiting: 29
Ph III recruiting: 2
Growth YoY: —
Industry share: 5%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (28)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02689336	Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors	withdrawn	Phase 2	0	Washington University School of MedicineOTHER	0	Sep 9, 2019	clinicaltrials
NCT03013387	Dosimetry Guided PRRT With 90Y-DOTATOC	withdrawn	Phase 2	0	Sue O'DorisioOTHER	0	Aug 25, 2017	clinicaltrials